Clinician perspective on molecular profiling of non-small-cell lung cancer
Data(s) |
2016
|
---|---|
Resumo |
The article by Meric-Bernstam et al1 that was recently published in Journal of Clinical Oncology raises important questions about the clinical application of large-scale genomic testing. We congratulate the authors for this ambitious study, which successfully profiled 2,000 consecutive patients with advanced cancer. The next-generation sequencing (NGS) platform was used for 1,749 of 2,000 patients (87.5%). Of 789 patients with potentially actionable mutations, 83 (11%, or 4% of screened population) were enrolled in a genomically matched clinical study. As the editorial2 accompanying the article by Meric-Bernstam et al1 pointed out, the 4% figure, albeit disappointing, may be an underestimate because cancers such as lung adenocarcinoma and melanoma, for which ≥ 50% of patients have actionable mutations, were under-represented. ... |
Identificador | |
Publicador |
American Society of Clinical Oncology |
Relação |
DOI:10.1200/JCO.2015.65.2040 Decatris, Marios P., Farrugia, David, & O'Byrne, Kenneth J. (2016) Clinician perspective on molecular profiling of non-small-cell lung cancer. Journal of Clinical Oncology, 34(8), pp. 884-886. |
Fonte |
School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation |
Palavras-Chave | #NSCLC #adenocarcinoma #genomic testing #melanoma |
Tipo |
Journal Article |